文献速递青光眼

Rho激酶抑制剂AR-12286逆转小鼠眼中类固醇诱导的眼压、有效滤过面积及形态学改变

Rho Kinase Inhibitor AR-12286 Reverses Steroid-Induced Changes in Intraocular Pressure, Effective Filtration Areas, and Morphology in Mouse Eyes.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

研究将56只C57BL/6小鼠随机分为生理盐水组、地塞米松组、地塞米松+AR-12286组和地塞米松停药组,发现AR-12286在一天内降低类固醇性高眼压小鼠的眼压(P<0.01),第5周末地塞米松+AR-12286组平均眼压较地塞米松组低约4 mm Hg(P<0.001)、较停药组低约2 mm Hg(P<0.05),并部分逆转小梁网形态学改变和有效滤过面积减少。

要点

  • AR-12286在一天内降低类固醇性高眼压小鼠眼压(P<0.01)。
  • 第5周末,地塞米松+AR-12286组平均眼压较地塞米松组低约4 mm Hg(P<0.001)。
  • AR-12286部分逆转地塞米松诱导的小梁网形态学改变和有效滤过面积减少。

核心结论

  • AR-12286逆转了类固醇诱导的小梁网形态学改变和有效滤过面积减少,这与类固醇性高眼压小鼠眼压降低相关。
  • 即使持续使用地塞米松,AR-12286降低类固醇性高眼压小鼠眼压升高的效果仍优于停用地塞米松。
  • 因此Rho激酶抑制剂可能降低依赖类固醇治疗患者的类固醇性高眼压。

研究设计与样本

  • 研究将56只C57BL/6小鼠随机分为生理盐水组、地塞米松组、地塞米松+AR-12286组和地塞米松停药组。
  • 前4周每周测量所有组眼压;从第5周开始,地塞米松停药组不治疗随访至眼压恢复正常,其余组按分组治疗并隔日测量眼压持续1周。
  • 向前房注射荧光示踪剂以观察小梁网流出模式并测定小梁网有效滤过面积;取高示踪区和低示踪区的径向切片进行电子显微镜检查。

主要发现

  • AR-12286在一天内降低类固醇性高眼压小鼠眼压(P<0.01)。
  • 第5周末,地塞米松+AR-12286组平均眼压较地塞米松组低约4 mm Hg(P<0.001),较地塞米松停药组低约2 mm Hg(P<0.05)。
  • AR-12286治疗1周(P<0.05)或停用地塞米松5周(P<0.01)后,地塞米松诱导的有效滤过面积减少得到恢复,小梁网形态学改变部分逆转。

临床怎么用

  • 原文结论认为Rho激酶抑制剂可能降低依赖类固醇治疗患者的类固醇性高眼压。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated mechanisms of reduction of intraocular pressure (IOP) by Rho kinase inhibitor AR-12286 in steroid-induced ocular hypertension (SIOH). METHODS: C57BL/6 mice (N = 56) were randomly divided into Saline, dexamethasone (DEX), DEX + AR-12286, and DEX-discontinuation (DEX-DC) groups. IOP was measured weekly during the first four weeks in all groups. Beginning at week 5, the DEX-DC group was followed without treatment until IOP returned to normal, and the other groups were treated as assigned with IOP measured every other day for another week. Fluorescent tracer was injected into the anterior chamber to visualize the outflow pattern in the trabecular meshwork (TM) and TM effective filtration area (EFA) was determined. Radial sections from both high- and low-tracer regions were processed for electron microscopy. RESULTS: AR-12286 reduced IOP in SIOH mouse eyes in one day (P < 0.01). At the end of week 5, mean IOP in the DEX + AR-12286 group was ∼4 mm Hg lower than DEX group (P < 0.001) and ∼2 mm Hg lower than DEX-DC group (P < 0.05). After one-week AR-12286 treatment (P < 0.05) or five-week DC of DEX (P < 0.01), DEX-induced reduction of EFA was rescued and DEX-induced morphological changes in the TM were partially reversed. CONCLUSIONS: AR-12286 reversed steroid-induced morphological changes in the TM and reduced EFA, which correlated with reduced IOP in SIOH eyes. AR-12286 reduced IOP elevation in SIOH eyes more effectively than discontinuing DEX treatment even when accompanied by continuous DEX treatment. Therefore Rho kinase inhibitors may lower SIOH in patients who rely on steroid treatment.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Ren R, Humphrey AA, Kopczynski C, et al. Rho Kinase Inhibitor AR-12286 Reverses Steroid-Induced Changes in Intraocular Pressure, Effective Filtration Areas, and Morphology in Mouse Eyes. Invest Ophthalmol Vis Sci. 2023. PMID: 36734964. doi:10.1167/iovs.64.2.7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。